Biosimulation Market (By Product: Software, Services; By Application: Drug Discovery, Drug Development, Others; By End User: Regulatory Authorities, harmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic Research Institutes; By Delivery Model: Subscription Models, Ownership Models) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023– 2032
The global biosimulation market size was valued at US$ 2.80 billion in 2022 and it is expected to hit over US$ 10.80 billion by 2032 with a registered CAGR of 14.50% from 2023 to 2032.
The U.S. biosimulation market size reached US$ 0.97 billion in 2022 and is predicted to touch US$ 3.79 billion by 2032, growing ata CAGR of 14.70% between 2023 to 2032.
North America held the largest revenue share of over 41% and led the global biosimulation market in 2022. The increased prevalence of various chronic diseases in the region, rising investments in the adoption of digital and automation technologies, and favorable government policies that support the growth of the pharmaceutical industries are the primary factors that has driven the growth of the North America biosimulation market. The in-silico models are gaining traction in the enforcement of the regulatory policy that helps in the standardization of treatment and increases patient safety.
Asia Pacific is expected to be the fastest-growing market in the forthcoming years. The region is expected to foresee a rapid growth in the investment towards the development of the healthcare and pharmaceutical industry. The presence of several top contract research organizations in the region along with the growing FDIs from the top pharmaceutical MNCs is significantly boosting the growth of the biosimulation market in Asia Pacific region. The availability of cheap factors of production and favorable government policies is supporting the development of the pharmaceutical and healthcare industries in this region, which is expected to foster the growth of the Asia Pacific biosimulation market in this region.
There has been an increase in the cases of drugs relapse owing to the drug resistant properties of several diseases such as cancer, bacterial infections, and tuberculosis, which is a key driver of the global biosimulation market growth. The rising research and development investments by the pharmaceutical companies, growing needs for controlling the costs of drug discovery, rising adoption of biosimilar and biologics industries, and rising adoption of biosimulation software among the regulatory authorities in various nations are the prominent factors that are fostering the growth of the global biosimulation market. The rising investments in the drug discovery are resulting in the increasing volume of clinical trials. There are very high chances of failures during the each phase of clinical trials.
The biosimulation can effectively reduce the risks of failure and can save a lot of costs associated with the research and development of numerous new drugs. The rising need for curtailing the drug development and clinical trial costs is propelling the demand for the biosimulation among the various pharmaceutical companies across the globe. The rapidly growing biopharmaceutical industry and a rapid increase in the number of numerous research organizations is spurring the demand for the biosimulation software and services across the globe. The rising technological advancements and growth in the adoption of new technologies in the global pharmaceutical industry is expected to propel the adoption of biosimulation in the forthcoming years.
| Report Coverage | Details |
| Market Size by 2032 | USD 10.80 Billion |
| Growth Rate from 2023 to 2032 |
CAGR of 14.4% |
| Packaging Segment Market Share in 2022 | 46% |
| Software Segment Makret Share in 2022 | 66% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Application, End User, Delivery Model, Geography |
| Companies Mentioned | Biovia, Certara, Compugen Inc., Genedata, In Silico Biosciences, Inc., Leadscope Inc., Pharmaceutical Product Development, LLC., Schrödinger, LLC., Simulations Plus, Inc., DassaultSystemes, Advanced Chemistry Development |
The software segment dominated the global biosimulation market garnering a market share of over 66% in 2022. This growth is attributable to the increased demand for the biosimulation software among the pharmaceutical companies and research organizations who are constantly involved in the research and development of various new drugs and diagnosis. Furthermore, the rising investments and favorable government support is fueling the activities related to the research studies, which is significantly boosting the growth of the software segment in the global market. The rising need for controlling healthcare costs and the drug development costs has fueled the demand for the software.
The services segment is projected to exhibit the highest CAGR during the forecast period. With the growing adoption of the biosimulation, the demand for the wide array of services associated with the biosimulation is expected to grow rapidly. The services offered by the biosimulation market players will facilitate the pharmaceutical companies and research organizations to curtail their costs.
The drug development was the leading segment that accounted for a revenue share of around 56% in 2022 and is expected to sustain its position throughout the forecast period. The extensive adoption of the biosimulation for controlling the costs in the drug development process has resulted in the dominance of this segment. The high risks associated with the failure of new drug development have fostered the growth of this segment across the globe. According to the US FDA, the biosimulation can be very useful as a predictive tool in the drug development process.
Drug discovery is anticipated to be the fastest-growing segment during the forecast period. The surging demand for the biosmulation in the pharmacogenetics and pharmacogenomics is expected to augment the growth of the drug discovery segment. The rising adoption of the biosimulation software in the research studies of various diseases is supplementing its growth.
Pharmaceutical & biotechnology was the dominant segment in 2022, which accounted for 51% market share. The demand for the biosimulation is higher in the pharmaceutical companies as they are constantly engaged in the drug discovery and drug development process. The increasing prevalence of various diseases among the global population and rising healthcare expenditure is supplementing the growth of the drug discovery market. The rising research and development expenses along with the increased need for controlling costs is a major factor that has fostered the growth of the pharmaceutical & biotechnology segment in the global biosimulation market.
The Contract research organizations (CROs) are expected to be the most opportunistic segment during the forecast period. The rising number of CROs across the globe owing to the increasing research activities with respect to producing desired results in a planned time period is fueling the adoption of the biosimulation software and services among the CROs.
The biosimulation market is moderately fragmented owing to the presence of several top market players. These market players are constantly involved in the various developmental strategies such as partnerships, mergers, acquisitions, collaborations, new product launches, and various others to strengthen their position and increase their market share.
Segments Covered in the Report
By Product
By Application
By End User
By Delivery Model
By Geography
If you have questions about this insights, please email at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Access TOC
Get a Sample